See more : Novozymes A/S (NVZMY) Income Statement Analysis – Financial Results
Complete financial analysis of NeueHealth, Inc. (NEUE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeueHealth, Inc., a leading company in the Medical – Equipment & Services industry within the Healthcare sector.
- Shaoxing BSM Chemical Co., Ltd. (300796.SZ) Income Statement Analysis – Financial Results
- ERecord Management, Inc. (ERMG) Income Statement Analysis – Financial Results
- ALR Technologies Inc. (ALRT) Income Statement Analysis – Financial Results
- CORPORATE BACKED CALL TR CTFS 7 (CBTRP) Income Statement Analysis – Financial Results
- Goldrich Mining Company (GRMC) Income Statement Analysis – Financial Results
NeueHealth, Inc. (NEUE)
About NeueHealth, Inc.
NeueHealth, Inc., a healthcare company, provides various healthcare services for health consumers, providers, and payors in the United States. It operates through two segments: NeueCare and NeueSolutions. The NeueCare segment delivers healthcare services to ACA marketplace, medicare, and medicaid through owned and affiliated clinics. It operates risk-bearing clinics under the Centrum Health, AssociatesMD, and Premier Medical Associates brand names. The company also offers integrated system care solution, such as embedded pharmacy, laboratory, radiology, and population health focused specialty services; and chronic care management, transitions of care, and referral management services. The NeueSolutions segment enables providers and medical groups to succeed in performance-based arrangements; and participates in the centers for healthcare access to medicare beneficiaries. The company was formerly known as Bright Health Group, Inc. and changed its name to NeueHealth, Inc. in January 2024. NeueHealth, Inc. was incorporated in 2015 and is headquartered in Doral, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.16B | 751.16M | 1.51B | 514.89M | 280.67M | 130.63M |
| Cost of Revenue | 996.58M | 662.97M | 1.29B | 451.92M | 0.00 | 0.00 |
| Gross Profit | 164.22M | 88.19M | 218.88M | 62.97M | 280.67M | 130.63M |
| Gross Profit Ratio | 14.15% | 11.74% | 14.47% | 12.23% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 19.43M | 0.00 | 0.00 |
| General & Administrative | 259.16M | 315.11M | 388.55M | 168.97M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 82.34M | 76.92M | 34.56M | 0.00 | 0.00 |
| SG&A | 259.16M | 315.11M | 465.48M | 203.53M | 180.49M | 95.84M |
| Other Expenses | 482.06M | 784.00K | 1.23M | -413.12M | -181.02M | -96.87M |
| Operating Expenses | 741.22M | 385.16M | 562.50M | 233.35M | 181.02M | 96.87M |
| Cost & Expenses | 1.75B | 1.05B | 1.86B | 685.27M | -405.41M | -193.27M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 38.20M | 12.82M | 7.23M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 18.30M | 30.71M | 35.05M | 8.29M | 1.13M | 1.03M |
| EBITDA | -566.80M | -246.39M | -308.58M | -249.31M | -124.20M | -61.61M |
| EBITDA Ratio | -48.83% | -32.80% | -20.28% | -31.48% | 0.40% | 0.79% |
| Operating Income | -577.00M | -368.76M | -343.63M | -170.38M | -125.34M | -62.64M |
| Operating Income Ratio | -49.71% | -49.09% | -22.71% | -33.09% | -44.66% | -47.95% |
| Total Other Income/Expenses | -52.17M | -84.61M | -6.00M | -3.80M | 0.00 | 0.00 |
| Income Before Tax | -629.17M | -381.58M | -349.63M | -170.38M | -125.34M | -62.64M |
| Income Before Tax Ratio | -54.20% | -50.80% | -23.11% | -33.09% | -44.66% | -47.95% |
| Income Tax Expense | -1.43M | 3.66M | -26.52M | -9.16M | 0.00 | 0.00 |
| Net Income | -1.15B | -1.46B | -1.18B | -248.44M | -125.34M | -62.64M |
| Net Income Ratio | -99.19% | -193.77% | -78.31% | -48.25% | -44.66% | -47.95% |
| EPS | -150.94 | -185.00 | -241.66 | -32.30 | -16.03 | -8.01 |
| EPS Diluted | -150.94 | -185.00 | -241.66 | -32.30 | -16.03 | -8.01 |
| Weighted Avg Shares Out | 7.95M | 7.87M | 4.90M | 7.69M | 7.82M | 7.82M |
| Weighted Avg Shares Out (Dil) | 7.95M | 7.87M | 4.90M | 7.69M | 7.82M | 7.82M |
NeueHealth, Inc. (NEUE) Q3 2024 Earnings Conference Call Transcript
Neuehealth Reports Third Quarter 2024 Results
NeueHealth Acquires Full Ownership of Centrum Health
NeueHealth (NEUE) Upgraded to Buy: What Does It Mean for the Stock?
NeueHealth, Inc. (NEUE) Q2 2024 Earnings Call Transcript
NeueHealth Secures up to $150 Million in New Term Loan Facility with Hercules Capital
NeueHealth Receives NYSE Non-Compliance Letter Regarding Market Capitalization Requirements
The Cigna Group (NYSE:CI) and NeueHealth (NYSE:NEUE) Financial Analysis
NeueHealth, Inc. (NEUE) Q1 2024 Earnings Call Transcript
NeueHealth Reports First Quarter 2024 Results
Source: https://incomestatements.info
Category: Stock Reports